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PreviewsChronic excess of metabolic factors
(e.g., glucose, lipids) promotes formation
of large, multiprotein complexes called in-
flammasomes. NOD-like receptor (NLR)
proteins are key components of inflam-
masomes, facilitating caspase-1 matura-
tion and secretion of cytokines in re-
sponse to cellular danger (Schroder
et al., 2010; Vandanmagsar et al., 2011).
The NLRP3 inflammasome in particular
functions as a sensor of metabolic stress
activated by high glucose and reactive
oxygen species (ROS) (Zhou et al.,
2010). Thanks to the current studies
(Lerner et al., 2012; Oslowski et al.,
2012), the relationship between ER stress
and the inflammasome is now clarified.
With increased levels of TXNIP, the
antioxidant function of thioredoxins are
dampened, further increasing ROS, and
binding of TXNIP to NLRP3 is promot-
ed, activating caspase-1 cleavage, inter-
leukin (IL)-1b secretion and pyroptosis.
In support of this, inducing TXNIP expres-
sion increased caspase-3 cleavage and
cell death in insulinoma cells, and pre-
treating human primary islets with IL-1
receptor antagonist reduced IL-1b andIL-6 expression and caspase-3/-7 activity
to ER stress agents (Oslowski et al.,
2012). TXNIP is therefore suggested
to serve as a wye switch that can redi-
rect the cell-fate railway track from an
adaptive outcome to a terminal UPR
(Figure 1).
Human conditions such as Wolfram
syndrome type 1 ascribe loss of b cells
to unmitigated ER stress and activation
of the UPR. Significant levels of ER stress
in b cells can also be the consequence of
continued exposure to free fatty acids and
cytokines (Hummasti and Hotamisligil,
2010). By identifying a novel path in the
pathogenesis of diabetes, the current
studies are foundational to the develop-
ment of new treatment approaches. Im-
portantly, Lerner et al. (2012) show that
a drug that inhibits IRE1a endoribonu-
clease activity without affecting its kinase
activity (STF-083010) reduces TXNIP ex-
pression and inflammasome activation
in b cells. It is hopeful that this or other
novel small-molecule inhibitors of this
pathway can be tailored toward the treat-
ment of diabetes and/or other degenera-
tive diseases.Cell Metabolism 1REFERENCES
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The opioid system plays a pivotal role in how our brain regulates hedonic components of ingestive behavior.
Duraffourd et al. (2012) add the gut to this opioid landscape, demonstrating direct activation of periportal
m-opioid receptors by food-derived opioid peptides (nutropioids), and a gut-brain feedback spiral that culmi-
nates in enhanced satiety.For centuries, everybody—from choco-
late lovers to steak aficionado—has
agreed on the addictive reward of certain
foods. In fact, ‘‘food cravings’’ have
been shown to override even the stron-
gest homeostatic drive. Their neuroana-
tomical and molecular underpinnings
suggest striking similarities with central
opioidergic mechanisms previously iden-
tified to mediate classic drug addictions.Accordingly, opioid receptors in the brain
have been shown to orchestrate multiple
hedonic components of ingestive be-
havior. An elegant study recently pub-
lished in Cell now also introduces the gut
as a potential control center for opioid
response circuits regulating food intake
(Duraffourd et al., 2012).
Opioid control of food intake has
been studied for several decades. Endog-enous opioid peptides such as endor-
phinswere first identified in 1975 (Hughes,
1975). Today, the current model suggests
that opioid signaling, especially via the
m-opioid receptor (MOR), is a major
driver of both the ‘‘wanting’’ (i.e., incentive
motivation and appetite) and ‘‘liking’’
(i.e., pleasure and palatability) aspects of
ingestive behavior. ‘‘Nutropioids,’’ i.e.,
opioid oligopeptides derived from food,6, August 8, 2012 ª2012 Elsevier Inc. 137
Figure 1. Schematic View of Nutropioid-Induced Satiety
Oligopeptides with opioid activity absorbed from the intestinal lumen after partial proteolytic digestion of
alimentary proteins (1) act as effectors for m-opioid receptors (MOR) present at the periportal neural
system (2). MOR signals projecting to central nervous system circuits via afferent fibers (3) induce intes-
tinal gluconeogenesis enzymes and intestinal glucose production (IPG, 4). The increase of portal glucose
concentrations (5) is sensed by portal glucose sensors and exerts glucose-induced satiety via homeo-
static and hedonic food intake (FI) control centers (6). Inset: Gut-brain feedback spiral of nutropioid-
induced satiety. FI, food intake; PVN, paraventricular nucleus; ARC, arcuate nucleus; LH, lateral hypothal-
amus; VTA, ventral tegmental area; PAG, periaqueductal gray; PBN, parabrachial nucleus; NTS, nucleus
of the tractus solitarius; CNS, central nervous system.
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Previewshad also been known for years. However,
their physiological relevance remained
unclear andcontroversial (Teschemacher,
2003).
Duraffourd et al. (2012) demonstrate
that satiety effects induced by protein-
enriched diets (PED) can be attributed to
such nutropioids and opioid antagonism
at the level of MORs, which are localized
in the periportal neural system (Duraf-
fourd et al., 2012). The authors first
show MOR-dependent regulation of
intestinal gluconeogenesis (IGP) by using
portal infusions of MOR effectors in
combination with a metabolic glucose
tracer in conscious rodents. Immunohis-
tochemical studies reveal the close prox-
imity of MORs and neuronal fibers in the
portal vein walls. The authors further
observe that MOR antagonist-induced
activation of neurons in brain regions,
which is implicated in the increased food
consumption, is abrogated by capsaicin
treatment and vagotomy; infusion of
MOR agonists reverses the PED-medi-
ated activation of neurons. The authors138 Cell Metabolism 16, August 8, 2012 ª201further show both in vivo and in vitro that
proteolytic digests and selectedoligopep-
tides mainly act as MOR antagonists.
Consistent with the notion that MORs
control a gut-brain circuit, MOR-knockout
mice are insensitive to oligopeptide-
induced intestinal gluconeogenesis and
PED-mediated satiety. Furthermore,
MOR antagonists are unable to induce
food intake in glucose-6-phosphatase-
deficient mice that lack intestinal gluco-
neogenesis, supporting the concept that
gut glucose can play a key mediatory
role (Duraffourd et al., 2012). Overall, Du-
raffourd and colleagues (2012) suggest
a model (Figure 1) where MOR-regulated
food intake depends on a complex spiral
feedback that involves release of nutro-
pioids into the portal vein, which in turn
antagonizes MOR receptors in periportal
neurons. These ascending neurons in-
crease the expression of intestinal gluco-
neogenic genes via a CNS relay, leading
to the release of glucose into portal
circulation. Consequently, the increased
glucose concentration in portal circula-2 Elsevier Inc.tion activates ascending glucose-sensing
periportal neurons, which ultimately re-
duces food intake via hypothalamic nuclei
involved in the homeostatic and hedonic
regulation of ingestive behavior.
Despite the elegance of Duraffourd’s
model of nutropioid action, multiple
questions remain and some new ones
emerge. How do changes in dietary
macronutrients alter the nutropioid gut-
brain circuitry? It would be of interest
for instance to examine whether the
popular Atkins diet—with its abundance
of alimentary protein but low carbohy-
drate content—exerts some of its
anorexigenic and weight-lowering impact
through MOR nutropioid ligands. Would
there be ‘‘nutropioid’’-rich and -poor
versions of the Atkins diet, and would
those have differential effects on
adiposity, appetite, and systemic metab-
olism? Bariatric surgery had been shown
to immediately decrease hedonic drive
toward hunger (Schultes et al., 2010).
Could such effects be mediated via
changes in nutropioid levels, or via
a modulation of signaling events at the
level of portal vein MORs? It is particu-
larly intriguing that alimentary peptides
seem to act solely as opioid antagonists
at portal MORs. Digestion of alimentary
proteins will however result in a complex
oligopeptide mixture of opioid antago-
nists and agonists. In fact, most alimen-
tary opioid ligands identified to date,
e.g., casomorphin from milk casein or
exorphin from gluten, were classified as
opioid agonists. Only long-term dietary
studies, or chronic portal infusions of
defined ratios of MOR agonists versus
antagonists, could help to delineate the
complexity of nutropioid action. Nutro-
pioids may also activate MORs residing
within the gut mucosal layer in a similar
fashion as the gut hormone cholecystoki-
nine (CCK), which has been show to
induce intestinal glucose production after
intraduodenal infusion (Breen et al.,
2011). Nutropioid action might further
not be restricted to periportal MORs,
but could also involve d- or k-opioid
receptors, which have been implicated
in the regulation of food reward and
food addiction (Gosnell et al., 1986). An
intriguing possibility finally arises from
recent studies that support a major role
for gut microbiota in the etiology of
obesity (Turnbaugh et al., 2006). Could
certain species of gut bacteria produce
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Previewsmicrobial opioids, or facilitate conversion
of alimentary oligopeptides into potent
MOR ligands? Microbial MOR agonists
have been identified before, such as the
ultrapotent dermorphins or deltorphins,
opioid agonists up to 40 times more
potent than morphine that have been iso-
lated from the skin of giant leaf frogs of
the genus Phyllomedusa. Albeit highly
speculative, such a potential interaction
of our gut flora and the nutropioid gut-
brain circuitry could add interesting future
perspectives to an already fascinating
research field.
The work by Duraffourd et al. (2012)
may not replace the currently accepted,
classical model of opioidergic food
intake control, which suggests the central
release of endogenous opioids as themajor stimulus for a hedonic drive to
consume food. Nonetheless, Duraffourd
et al. (2012) expand a CNS-centric view
to a model that also allows direct
peripheral action of alimentary opioid
antagonists on periportal MORs, followed
by the (IGP-dependent) decrease in food
consumption. The strength of this new
model lays in the integration of both
worlds; direct effects of alimentary ‘‘nu-
tropioids’’ could be followed by—or
compete—with a concomitant increase
in endogenous opioids, such as b-endor-
phin (which could be released by both the
GI tract and the CNS). Thus, exogenous
and endogenous opioids could orches-
trate hedonic feedingmechanisms atmul-
tiple sites, both in the periphery and in
the CNS.Cell Metabolism 1REFERENCES
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Why upregulation of the transcription factor Nrf2 increases tumor cell proliferation is unclear. Mitsuishi et al.
(2012) now provide evidence that Nrf2 augments purine nucleotide synthesis, thus supporting tissue hyper-
trophy. This change in cellular metabolism requires loss of Nrf2 repression by Keap1 as well as costimulation
via the PI3K-Akt pathway.NF-E2 p45-related factor 2 (Nrf2, also
called Nfe2l2) is a cap ‘n’ collar (CNC)
basic-region leucine zipper (bZIP) tran-
scription factor that allows cells to adapt
to oxidative stress and electrophiles by
mediating induction of a battery of cyto-
protective genes, including those encod-
ing enzymes involved in the synthesis
of reduced glutathione (GSH), repair of
oxidized protein thiols, scavenging of
reactive oxygen species (ROS), and
drug metabolism (Hayes et al., 2010).
The stress-responsive activity of Nrf2 is
dictated at the level of protein stability,
which is controlled by the ubiquitin
ligase substrate adaptor Kelch-like ECH-associated protein (Keap1). In normal
unstressed cells, Nrf2 protein is rapidly
turned over in a Keap1-dependent
manner through Cul3-Rbx1 ubiquitylation
and proteasomal degradation. However,
Keap1 is inactivated by ROS and electro-
philes, and such agents stabilize Nrf2
protein and cause induction of Nrf2-
target genes (McMahon et al., 2010). By
contrast with normal cells, Nrf2 protein
is constitutively upregulated in many
tumors due to somatic mutations in the
Keap1 or Nrf2 genes. Tumors that over-
express Nrf2 exhibit increased resistance
to chemotherapeutic drugs and higher
rates of proliferation (Zhang et al., 2010),though it is unclear why the latter occurs.
It has been suggested that Nrf2 might
increase phosphorylation of retinoblas-
toma protein and prevent cell-cycle arrest
(Homma et al., 2009) or that Nrf2 might
allow tumors to survive the high levels
of ROS that K-Ras, B-Raf, and Myc
oncogenes produce (DeNicola et al.,
2011). Given that cancer cells are
subject to metabolic reprogramming to
support rapid synthesis of macromole-
cules (Ward and Thompson, 2012), it is
also possible that Nrf2 promotes tumor
cell proliferation by influencing interme-
diary metabolism. In a recent, ground-
breaking study, Mitsuishi et al. (2012)6, August 8, 2012 ª2012 Elsevier Inc. 139
